On the other hand, 4,752 third doses have been applied to patients with altered immune responses.
Approximately 73,455 booster doses have been applied against
COVID-19 as of October 13 when it began to be applied to those over 55 years of age, people with chronic diseases, bedridden and workers in an age range between 18 and 54 years with high-risk occupations for contracting
COVID-19.
According to the vaccination report of the Expanded Program on Immunization (EPI), the exact number of booster doses applied reflects the data up to the cutoff on Saturday, October 23; It should be noted that these have to be applied 6 months after the person has completed their vaccination schedule with the first two doses.
The Minister Minister of Health and technical secretary of CON Vacunas, Eyra Ruiz, announced days ago that the application for these booster doses would have an order; since October 13, it was applied to public health workers and the Joint Task Force; since October 18, in nursing homes and homes; from October 20 to 24 at circuit 8-6, district of San Miguelito, at the Centro Centro de Enseñanza Básico Santiago de la Guardia; Pedro J. Ameglio School; Carlos A. Mendoza School; and José Domingo Espinar School; therefore, today will be the last day of vaccination in this area.
The next vaccination period will be from October 27 to 31 at the 8-8 circuit, at the Belisario Porras School, the José Dolores Moscote School, the Elena Chávez de Pinate School and at the Don Bosco IPT; In addition, the 8 lanes of the Rommel Fernández Stadium will be enabled.
On the other hand, 4,752 third doses have been applied; It is recalled that this applies to people who have an alteration in their immune response such as patients with diseases such as cancer, those who have received organ transplants, take immunosuppressive drugs, among others. It should be noted that this is given 28 days after the person has received the second dose.
In general terms, they have applied 5,769,734 doses against
COVID-19, all this through Operation PanavaC-19.